271 related articles for article (PubMed ID: 34275094)
1. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
2. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
4. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
[TBL] [Abstract][Full Text] [Related]
5. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery.
Zielinski G; Ozdarski M; Maksymowicz M; Szamotulska K; Witek P
Front Endocrinol (Lausanne); 2020; 11():439. PubMed ID: 32733387
[No Abstract] [Full Text] [Related]
6. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
7. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
Park JY; Choi W; Hong AR; Yoon JH; Kim HK; Jang WY; Jung S; Kang HC
Pituitary; 2021 Dec; 24(6):955-963. PubMed ID: 34189717
[TBL] [Abstract][Full Text] [Related]
8. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
[TBL] [Abstract][Full Text] [Related]
9. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.
Babey M; Sahli R; Vajtai I; Andres RH; Seiler RW
Pituitary; 2011 Sep; 14(3):222-30. PubMed ID: 21170594
[TBL] [Abstract][Full Text] [Related]
10. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.
Giese S; Nasi-Kordhishti I; Honegger J
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):163-171. PubMed ID: 33461233
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
Sala E; Bellaviti Buttoni P; Malchiodi E; Verrua E; Carosi G; Profka E; Rodari G; Filopanti M; Ferrante E; Spada A; Mantovani G
J Endocrinol Invest; 2016 Dec; 39(12):1377-1382. PubMed ID: 27245604
[TBL] [Abstract][Full Text] [Related]
13. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
16. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.
Kreutzer J; Buslei R; Wallaschofski H; Hofmann B; Nimsky C; Fahlbusch R; Buchfelder M
Eur J Endocrinol; 2008 Jan; 158(1):11-8. PubMed ID: 18166812
[TBL] [Abstract][Full Text] [Related]
17. Surgery for prolactinomas: a better choice?
Honegger J; Nasi-Kordhishti I; Aboutaha N; Giese S
Pituitary; 2020 Feb; 23(1):45-51. PubMed ID: 31853793
[TBL] [Abstract][Full Text] [Related]
18. Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis.
Yagnik KJ; Erickson D; Bancos I; Atkinson JLD; Choby G; Peris-Celda M; Van Gompel JJ
Pituitary; 2021 Dec; 24(6):978-988. PubMed ID: 34580821
[TBL] [Abstract][Full Text] [Related]
19. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
20. Long-term Discontinuation of Dopamine Agonist Treatment in Patients with Prolactinomas Revisited.
Sosa-Eroza E; Espinosa-Cárdenas E
Arch Med Res; 2023 Dec; 54(8):102893. PubMed ID: 37806785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
